Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Literature
1.
Colina F, Molero A, Casıs B, Martınez-Montiel P. Infliximab-related hepatitis: a case study and literature review. Dig Dis Sci. 2013;58:3362–3367.PubMedCrossRef
2.
Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor alpha antagonists: analysis of thirty-four cases. Clin Gastroent Hepatol. 2013;11:558–564.CrossRef
3.
Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol. 2007;26:578–581.
4.
Goujon C, Dahel K, Bérard F, Guillot I, Gunera-Saad N. Autoimmune hepatitis in two psoriasis patients treated with infliximab. J Am Acad Dermatol. 2010;63:43–44.CrossRef
5.
Bezabeh S, Flowers C, Kortepeter C, et al. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther. 2010;31:1028–1035.PubMed
6.
Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol. 2011;55:747–749.PubMedCrossRef
7.
Germano V, Picchianti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis.. 2005;64:1519–1520.PubMedCentralPubMedCrossRef
8.
Subramaniam K, Chitturi S, Brown M. Infliximab-induced autoimmune hepatitis in Crohn’s disease treated with budesonide and mycophenolate. Inflamm Bowel Dis. 2011;17:E149–E150.PubMedCrossRef
Metadata
Title
Hepatotoxicity of Anti-TNF Agents
Authors
Maurizio Bonacini
Marwan Ghabril
Herbert L. Bonkovsky
Publication date
01-05-2014
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3109-3

Other articles of this Issue 5/2014

Digestive Diseases and Sciences 5/2014 Go to the issue

Original Article

Improved Post-Transplant Survival in the United States for Patients with Cholangiocarcinoma After 2000

Original Article

Epigallocatechin Gallate Does Not Accelerate the Early Phase of Liver Regeneration After Partial Hepatectomy in Rats

Editorial

Endoscopic Papillary Balloon Dilation Versus Sphincterotomy for Removal of Small Common Bile Duct Stones in Young Patients: Unresolved Issues for an Expanding Technique

Original Article

Reverse-Phase Protein Array Analysis to Identify Biomarker Proteins in Human Pancreatic Cancer

Review

SEDASYS®, Airway, Oxygenation, and Ventilation: Anticipating and Managing the Challenges

Original Article

Comparison of Endoscopic Papillary Balloon Dilation and Sphincterotomy in Young Patients with CBD Stones and Gallstones
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits